22.75
08-October-24 12:22:10
15 minutes delayed
Stocks
-1.45
-5.99%
Today's range
22.48 - 26.15
ISIN
N/A
Source
NASDAQ
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
30 Sep 2024 08:00:00 By Nasdaq GlobeNewswire
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
16 Sep 2024 16:05:00 By Nasdaq GlobeNewswire